XPH(SZ:300147)2021-10-27 16:00Financial Performance - The company's revenue for Q3 2021 was ¥700,940,780, representing a 3.38% increase compared to ¥678,000,020 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥33,412,770, a decrease of 595.06% from a profit of ¥6,749,185 in the previous year[4]. - Total operating revenue for Q3 2021 was CNY 2,236,452,584.17, a decrease of 10.35% compared to CNY 2,494,461,040.41 in the same period last year[20]. - Net profit for Q3 2021 was CNY 47,734,307.87, a significant decline of 73.5% from CNY 180,045,818.85 in Q3 2020[22]. - The net profit attributable to shareholders of the parent company was CNY 16,894,395.35, down 88.6% from CNY 147,886,620.46 in the previous year[22]. - The company reported a total comprehensive income of CNY 48,668,039.84, compared to CNY 178,656,822.52 in Q3 2020, a decrease of 72.8%[22]. Cash Flow - The net cash flow from operating activities increased by 1460.23%, reaching ¥168,367,470 compared to a loss of ¥12,377,840 in the previous year[4]. - The net cash flow from operating activities was 168,367,470.08 CNY, a significant improvement compared to a loss of 12,377,848.16 CNY in the previous period[25]. - Total cash inflow from operating activities was 2,383,865,867.55 CNY, down 10.55% from 2,665,729,201.18 CNY in the prior period[25]. - Cash outflow from operating activities totaled 2,215,498,397.47 CNY, a decrease of 17.29% from 2,678,107,049.34 CNY in the previous period[25]. - The net cash flow from investing activities was -304,319,283.56 CNY, an improvement from -829,642,669.40 CNY in the prior period[26]. - Cash inflow from financing activities was 3,577,598,708.10 CNY, an increase from 3,075,980,000.00 CNY in the previous period[26]. - The net cash flow from financing activities was -196,824,471.30 CNY, compared to a positive flow of 1,370,285,846.44 CNY in the prior period[26]. - The ending balance of cash and cash equivalents was 144,566,701.01 CNY, down from 862,078,289.23 CNY in the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,636,374,813.18, a decrease of 4.59% from ¥12,196,636,876.12 at the end of the previous year[5]. - Total liabilities decreased to CNY 7,176,204,513.48 from CNY 7,947,453,059.37, a decline of 9.7%[18]. - The total equity of the company reached approximately CNY 4.25 billion, with total assets amounting to CNY 12.20 billion[31]. - The company holds CNY 725.72 million in long-term loans and CNY 221.20 million in bonds payable[30]. - The report indicates a total of CNY 85.01 million in contract liabilities, reflecting future revenue obligations[30]. Investments and R&D - The company reported a significant increase in R&D expenses by 44.18%, indicating higher investment in ongoing projects[10]. - The company's R&D expenses increased to CNY 49,336,607.34, up from CNY 34,219,547.32, representing a growth of 44.3%[21]. - The company made a strategic investment in SIRNAOMICS LTD, resulting in a 114.18% increase in other non-current financial assets[10]. - The company experienced a 67.25% increase in other income related to government subsidies, reflecting enhanced support from governmental policies[10]. - The company reported a 16247.33% increase in cash received from investments, indicating a significant inflow from new investments[10]. Shareholder Information - The company’s major shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 26.22% of the shares, with a total of 173,390,578 shares pledged[13]. - The total owner's equity attributable to shareholders is approximately CNY 3.61 billion[31]. Miscellaneous - The company has not undergone an audit for the third quarter report[32]. - The report was released by the board of directors on October 27, 2021[33].